Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

References for PMC Articles for PubMed (Select 20530581)


PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.

Desai S, Bolick SC, Maurin M, Wright KL.

J Immunol. 2009 Nov 1;183(9):5778-87. doi: 10.4049/jimmunol.0901120. Epub 2009 Oct 14.


Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Nasta S, O'Connor OA, Shi H, Boral AL, Fisher RI.

Ann Oncol. 2009 Mar;20(3):520-5. doi: 10.1093/annonc/mdn656. Epub 2008 Dec 12.


The endoplasmic reticulum stress response in immunity and autoimmunity.

Todd DJ, Lee AH, Glimcher LH.

Nat Rev Immunol. 2008 Sep;8(9):663-74. doi: 10.1038/nri2359. Review.


Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.

Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S.

Mol Cancer. 2008 May 19;7:40. doi: 10.1186/1476-4598-7-40.


Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.

Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, Daibata M, Lai R, Wiestner A.

Leuk Lymphoma. 2008 Apr;49(4):798-808. doi: 10.1080/10428190801910912.


Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.

Jares P, Colomer D, Campo E.

Nat Rev Cancer. 2007 Oct;7(10):750-62. Review.


Bortezomib for the treatment of mantle cell lymphoma.

Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4.


Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.


Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.

Liu YY, Leboeuf C, Shi JY, Li JM, Wang L, Shen Y, Garcia JF, Shen ZX, Chen Z, Janin A, Chen SJ, Zhao WL.

Blood. 2007 Jul 1;110(1):339-44. Epub 2007 Mar 22.


Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia.

Gehen SC, Vitiello PF, Bambara RA, Keng PC, O'Reilly MA.

Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L716-24. Epub 2006 Nov 3.


The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells.

Ocaña E, González-García I, Gutiérrez NC, Mora-López F, Brieva JA, Campos-Caro A.

Haematologica. 2006 Nov;91(11):1579-80. Epub 2006 Oct 17.


Blimp1 defines a progenitor population that governs cellular input to the sebaceous gland.

Horsley V, O'Carroll D, Tooze R, Ohinata Y, Saitou M, Obukhanych T, Nussenzweig M, Tarakhovsky A, Fuchs E.

Cell. 2006 Aug 11;126(3):597-609.


Treatment of mantle cell lymphoma: current approach and future directions.

Brody J, Advani R.

Crit Rev Oncol Hematol. 2006 Jun;58(3):257-65. Review.


BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response.

Doody GM, Stephenson S, Tooze RM.

Eur J Immunol. 2006 Jun;36(6):1572-82.


Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells.

Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, Kouzarides T, Surani MA.

Nat Cell Biol. 2006 Jun;8(6):623-30. Epub 2006 May 14.


PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.

Garcia JF, Roncador G, García JF, Sánz AI, Maestre L, Lucas E, Montes-Moreno S, Fernandez Victoria R, Martinez-Torrecuadrara JL, Marafioti T, Mason DY, Piris MA.

Haematologica. 2006 Apr;91(4):467-74.


Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance.

Kallies A, Hawkins ED, Belz GT, Metcalf D, Hommel M, Corcoran LM, Hodgkin PD, Nutt SL.

Nat Immunol. 2006 May;7(5):466-74. Epub 2006 Mar 26.


Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH.

Blood. 2006 Jun 15;107(12):4907-16. Epub 2006 Feb 28.


Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.

Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R.

J Exp Med. 2006 Feb 20;203(2):311-7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk